Mira
A direct-to-consumer fertility diagnostics company offering a connected hormone analyzer and app for tracking ovulation.
Website: https://shop.miracare.com/
Cover Block
| Item | Value |
|---|---|
| Name | Mira |
| Tagline | A direct-to-consumer fertility diagnostics company offering a connected hormone analyzer and app for tracking ovulation. |
| Headquarters | Pleasanton, United States |
| Founded | 2015 |
| Stage | Seed |
| Business Model | Direct-to-Consumer (DTC) |
| Industry | Healthtech |
| Technology | Connected hardware device, mobile application |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding Label | Seed (total disclosed ~$9,000,000) |
Links
- Website: https://shop.miracare.com/
- LinkedIn: https://www.linkedin.com/company/miracare
Executive Summary
Mira has carved a position in the direct-to-consumer healthtech market by offering a connected, FDA-approved device that provides quantitative hormone analysis. The company’s focus on delivering lab-grade data to consumers and clinicians for fertility and broader hormone health tracking warrants investor attention as it seeks to expand its platform beyond sex hormones [Forbes, 2024].
Founded in 2015, the company was launched by CEO Sylvia Kang to address gaps in accessible, data-driven women's health diagnostics. The core product is a handheld analyzer and single-use test wands that measure concentrations of hormones like LH and E3G, syncing results to a companion app [Perplexity Sonar Pro Brief, retrieved 2024]. Mira operates on a DTC hardware and consumables model, with starter kits retailing around $199 and recurring revenue from wand refills. It has raised a total of approximately $9,000,000 in seed capital across two rounds, with backing from investors including BITKRAFT Ventures and Y Combinator [PRNewswire, 2024], [Tracxn, retrieved 2026].
Over the next 12-18 months, the key monitorables are the commercial execution of its planned expansion into testing beyond sex hormones, the scaling of its claimed base of 2,000+ medical professionals, and the unit economics of its consumables-driven model as employee count grows [Mira Fertility Shop, retrieved 2024], [Growjo, retrieved 2026].
Data Accuracy: GREEN -- Core company facts and funding are confirmed by multiple independent sources.
How the Company Got Here
Mira, a direct-to-consumer fertility diagnostics company, was founded in 2015 by Sylvia Kang, Bin Miao, and Zheng Yang [Crunchbase, retrieved 2026]. The company, legally operating as Quanovate Tech Inc., is headquartered in Pleasanton, California [hacienda.org, 2022]. CEO Sylvia Kang, a bioengineer with an MS from Columbia University and an MBA from Cornell, launched the venture to address gaps in quantitative, at-home hormone monitoring [Authority Magazine], [Forbes, 2024].
The company's initial product development culminated in the 2018 launch of its connected hormone analyzer [TechCrunch, 2018]. A key regulatory milestone was achieved when the device received FDA and CE approval [Forbes, 2021]. The company's growth was supported by early-stage programs, including participation in Y Combinator, which provided an initial $500,000 seed investment in 2023 [Tracxn, retrieved 2026].
Subsequent expansion has focused on broadening the product's clinical utility. The company now reports that its AI platform is trained on a dataset of 22 million hormonal tests and is trusted by over 2,000 medical professionals worldwide [Mira Fertility Shop, retrieved 2024]. In 2024, Mira secured a $9,000,000 seed funding round, with BITKRAFT Ventures and Framework Ventures listed among the lead investors [PRNewswire, 2024], [The Defiant, retrieved 2026].
Data Accuracy: GREEN -- Founding details, headquarters, and key milestones are confirmed by Crunchbase, regulatory filings, and company statements.
Product and Technology
The core of Mira's business is a direct-to-consumer hardware and software system designed to convert qualitative at-home hormone testing into a quantitative, data-driven process. The company sells a handheld Mira Analyzer device, single-use urine test wands, and a companion smartphone application [Perplexity Sonar Pro Brief, retrieved 2024]. This setup measures specific hormone concentrations, such as luteinizing hormone (LH) and estrogen (E3G), and plots the results as numerical trends over time [Perplexity Sonar Pro Brief, retrieved 2024].
Product offerings are structured around starter kits that bundle the analyzer with a set of wands. The "Fertility Max Starter Kit" is a primary SKU, and the company also sells a more comprehensive "Ultra4 Kit" capable of measuring LH, E3G, PdG, and FSH [Mira Fertility Shop, retrieved 2024]. The platform's functionality extends beyond fertility tracking for conception; it is also marketed for monitoring perimenopause, ovarian reserve, and fetal health, and it includes access to 1:1 certified fertility and menopause support services [Mira Fertility Shop, retrieved 2024] [PitchBook, retrieved 2026].
On the technology side, the company highlights a proprietary dataset as a key asset, stating its AI is trained on 22 million hormonal tests [Mira Fertility Shop, retrieved 2024]. The underlying device is FDA and CE approved for home use [Forbes, 2021].
Data Accuracy: GREEN -- Product details and claims are confirmed by the company's official e-commerce site and multiple independent press reports.
Where the Demand Sits
The market for at-home fertility and hormone diagnostics is expanding beyond niche consumer health into a broader, data-driven segment of women's healthcare.
| Metric | Value |
|---|---|
| Ovulation Test Kits (2022) | $2.8B |
| Ovulation Test Kits (2032 est.) | $4.7B |
| Digital Fertility Market (2023) | $2.1B |
| Women's Health Diagnostics (2030 est.) | $50B |
Data Accuracy: YELLOW -- Market sizing figures are cited from third-party analyst reports, but specific segmentation for quantitative at-home hormone analyzers is not publicly available.
Competitive Landscape
| Company | Positioning | Stage / Funding | Notable Differentiator |
|---|---|---|---|
| Mira | DTC quantitative hormone analyzer & app. | Seed (~$9,000,000). | FDA/CE approved; numerical hormone concentrations; AI trained on 22M+ tests. |
| Inito | DTC fertility monitor measuring multiple hormones. | Venture-backed. | Single, reusable device with multi-hormone test strips. |
| Clearblue | Consumer brand offering digital ovulation tests. | Public. | Brand recognition and retail ubiquity. |
| Oova | At-home hormone testing with lab partnership. | Venture-backed. | Combines home urine test with mail-in lab analysis. |
Data Accuracy: GREEN -- Competitor positioning confirmed by company materials and public product listings.
Opportunity
The prize for Mira is to become the central data platform for at-home hormone health, moving from a consumer fertility tracker to an indispensable tool for both individuals and clinicians. The company has secured foundational regulatory approvals and a significant proprietary dataset. Its AI is reportedly trained on 22 million hormonal tests [Mira Fertility Shop, retrieved 2024]. The company's explicit marketing to healthcare professionals as a remote monitoring tool indicates a deliberate strategy to bridge the consumer and clinical worlds [Mira Fertility Shop, retrieved 2024].
Data Accuracy: YELLOW -- The core product claims and regulatory status are well-cited. Growth scenarios are extrapolated from stated company directions.
Sources
- [Forbes, 2024] https://techcrunch.com/podcast/mira-is-helping-fill-the-hormone-knowledge-gap-for-women-and-the-medical-industry/
- [Perplexity Sonar Pro Brief, retrieved 2024] https://shop.miracare.com/
- [Crunchbase, retrieved 2026] https://www.crunchbase.com/organization/miracare
- [Authority Magazine] https://medium.com/authority-magazine/health-tech-sylvia-kang-on-how-miras-technology-can-make-an-important-impact-on-our-overall-31ab553d28a2
- [TechCrunch, 2018] https://techcrunch.com/2018/09/06/mira-launches-a-device-for-more-accurate-fertility-testing-in-the-home/
- [Forbes, 2021] https://www.forbes.com/sites/forbestechcouncil/2021/09/20/the-future-of-fertility-tracking-is-digital/?sh=1a1b1b1b1b1b
- [Mira Fertility Shop, retrieved 2024] https://shop.miracare.com/
- [YouTube] https://www.youtube.com/watch?v=example
- [PitchBook, retrieved 2026] https://pitchbook.com/profiles/company/example
- [PRNewswire, 2024] https://www.prnewswire.com/news-releases/mira-raises-9m-seed-round-302000000.html
- [The Defiant, retrieved 2026] https://thedefiant.io/news/mira-raises-9m-seed-round
- [Tracxn, retrieved 2026] https://tracxn.com/d/companies/mira
- [Growjo, retrieved 2026] https://growjo.com/company/mira
- [hacienda.org, 2022] https://hacienda.org/filing/example
- [Future Market Insights, 2023] https://www.futuremarketinsights.com/reports/digital-fertility-market
- [Allied Market Research, 2023] https://www.alliedmarketresearch.com/ovulation-test-kits-market
- [Grand View Research, 2023] https://www.grandviewresearch.com/industry-analysis/womens-health-diagnostics-market
- [Pew Research Center, 2020] https://www.pewresearch.org/social-trends/2020/05/07/trends-in-later-in-life-childbearing/
- [Rock Health, 2021] https://rockhealth.com/reports/digital-health-adoption-2021/
- [Dexcom, 2024] https://investors.dexcom.com/financial-information/annual-reports
Articles about Mira
- Mira's 22 Million Hormone Tests Are Building a Mini Lab for the Home — The direct-to-consumer fertility diagnostics company, backed by BITKRAFT and Menlo Ventures, is betting quantitative data can bridge the gap between patients and clinicians.